PharmX Technologies Limited Fundamental Analysis
PharmX Technologies Limited (PHX.AX) shows weak financial fundamentals with a PE ratio of 133.33, profit margin of -12.44%, and ROE of -5.91%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 17.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze PHX.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakPHX.AX struggles to generate sufficient returns from assets.
Valuation Score
ModeratePHX.AX shows balanced valuation metrics.
Growth Score
WeakPHX.AX faces weak or negative growth trends.
Financial Health Score
ExcellentPHX.AX maintains a strong and stable balance sheet.
Profitability Score
WeakPHX.AX struggles to sustain strong margins.
Key Financial Metrics
Is PHX.AX Expensive or Cheap?
P/E Ratio
PHX.AX trades at 133.33 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, PHX.AX's PEG of 1.33 indicates fair valuation.
Price to Book
The market values PharmX Technologies Limited at 4.61 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 390.56 times EBITDA. This signals the market has high growth expectations.
How Well Does PHX.AX Make Money?
Net Profit Margin
For every $100 in sales, PharmX Technologies Limited keeps $-12.44 as profit after all expenses.
Operating Margin
Core operations generate -15.80 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-5.91 in profit for every $100 of shareholder equity.
ROA
PharmX Technologies Limited generates $-5.17 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
PharmX Technologies Limited produces operating cash flow of $853.26K, showing steady but balanced cash generation.
Free Cash Flow
PharmX Technologies Limited generates strong free cash flow of $842.25K, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
PHX.AX converts 0.97% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
133.33
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.33
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.61
vs 25 benchmark
P/S Ratio
Price to sales ratio
10.57
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.05
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.68
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.06
vs 25 benchmark
ROA
Return on assets percentage
-0.05
vs 25 benchmark
ROCE
Return on capital employed
-0.07
vs 25 benchmark
How PHX.AX Stacks Against Its Sector Peers
| Metric | PHX.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 133.33 | 36.10 | Worse (Expensive) |
| ROE | -5.91% | 731.00% | Weak |
| Net Margin | -12.44% | -141462.00% (disorted) | Weak |
| Debt/Equity | 0.05 | 0.46 | Strong (Low Leverage) |
| Current Ratio | 3.68 | 3.40 | Strong Liquidity |
| ROA | -5.17% | 237.00% | Weak |
PHX.AX outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews PharmX Technologies Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Growth, Innovation, High Beta
EPS CAGR
N/A
Industry Style: Growth, Innovation, High Beta
FCF CAGR
N/A
Industry Style: Growth, Innovation, High Beta